

RIBOMIC Announces Publication of anti-TGF- β 1 Aptamer Data Demonstrating Enhancement of anti-cancer Drug Efficacy

TOKYO, June 30, 2022 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced the publication of the preclinical data of its anti-TGF- β 1 aptamer demonstrating the enhancement of efficacy of anti-cancer drug, gefitinib, in non-small cell lung cancer xenograft model. The aptamer is being developed in collaboration with Project Associate Professor Masaki Takahashi at Project Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo.

Journal name	Molecular Therapy Nucleic Acids
Article title	Anti-TGF- β 1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model
Article URL	https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(22)00153-6

ABOUT RIBOMIC

RIBOMIC is a clinical stage bio-pharmaceutical company specializing in the discovery and development of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, rare disease of short stature in children and many other diseases.

See RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.

Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:

RIBOMIC Inc.

Finance and Accounting

ir.inquiry@ribomic.com